Topics

Mepolizumab gains FDA nod for pediatric severe eosinophilic asthma

06:33 EDT 13 Sep 2019 | SmartBrief

An expanded indication for GlaxoSmithKline's Nucala, or mepolizumab, gained the FDA's approval as a treatment for pediatric p -More

Original Article: Mepolizumab gains FDA nod for pediatric severe eosinophilic asthma

NEXT ARTICLE

More From BioPortfolio on "Mepolizumab gains FDA nod for pediatric severe eosinophilic asthma"

Quick Search

Relevant Topics

GlaxoSmithKline
GlaxoSmithKline is the third largest pharmaceutical company in the world, based on annual sales, which reached $37,134m in 2009. Spread over 100 countries, GSK employs 96,500 people, 13,000 of which are dedicated to research and development of the the ...

Pediatrics
Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...